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I-kappa-kinase-2 (IKK-2) inhibition potentiates
vincristine cytotoxicity in non-Hodgkin’s
lymphoma
Ayad Al-Katib1*†, Alan A Arnold2†, Amro Aboukameel1, Angela Sosin1, Peter Smith3, Anwar N Mohamed4,
Frances W Beck5, Ramzi M Mohammad6
Abstract
Background: IKK-2 is an important regulator of the nuclear factor-B (NF-B) which has been implicated in
survival, proliferation and apoptosis resistance of lymphoma cells. In this study, we investigated whether inhibition
of IKK-2 impacts cell growth or cytotoxicity of selected conventional chemotherapeutic agents in non-Hodgkin’s
lymphoma.
Two established model systems were used; Follicular (WSU-FSCCL) and Diffuse Large Cell (WSU-DLCL2) Lymphoma,
both of which constitutively express p-IB. A novel, selective small molecule inhibitor of IKK-2, ML120B (N-[6-
chloro-7-methoxy-9H-b-carbolin-8-yl]-2-methylnicotinamide) was used to perturb NF-B in lymphoma cells. The
growth inhibitory effect of ML120B (M) alone and in combination with cyclophosphamide monohydrate (C), doxor-
ubicin (H) or vincristine (V) was evaluated in vitro using short-term culture assay. We also determined efficacy of
the combination in vivo using the SCID mouse xenografts.
Results: ML120B down-regulated p-IBa protein expression in a concentration dependent manner, caused growth
inhibition, increased G0/G1 cells, but did not induce apoptosis. There was no significant enhancement of cell kill in
the M/C or M/H combination. However, there was strong synergy in the M/V combination where the vincristine
concentration can be lowered by a hundred fold in the combination for comparable G2/M arrest and apoptosis.
ML120B prevented vincristine-induced nuclear translocation of p65 subunit of NF-B. In vivo, ML120B was effective
by itself and enhanced CHOP anti-tumor activity significantly (P = 0.001) in the WSU-DLCL2-SCID model but did
not prevent CNS lymphoma in the WSU-FSCCL-SCID model.
Conclusions: For the first time, this study demonstrates that perturbation of IKK-2 by ML120B leads to synergistic
enhancement of vincristine cytotoxicity in lymphoma. These results suggest that disruption of the NF-B pathway
is a useful adjunct to cytotoxic chemotherapy in lymphoma.
Background
NHL is the fifth most common type of cancer in the US
representing 4.5% of cancer cases. Since the early 1970’s
the incidence of NHL has doubled [1]. It is a group of
heterogeneous diseases resulting from malignant trans-
formation of lymphocytes. Eighty-five percent of NHLs
are B-cells that can be broadly classified as aggressive
(50%) and indolent (40%). Diffuse Large B-cell NHL
(DLBCL) is the most common subtype (30%) of all lym-
phomas and is the prototype of aggressive but curable
NHL. Follicular lymphoma (FL) is the second most
common subtype, representing 22% and is the most
common indolent NHL [2,3].
To date, there is no consensus concerning the best
treatment algorithm, but combination chemotherapy has
been the mainstay for treatment of NHL. Incorporation
of the anti-CD20 monoclonal antibody, Rituximab, has
led to improvements in overall survival [4,5]. More than
half of patients with DLBCL can be cured with combi-
nation of Rituximab (R) and cyclophosphamide, doxoru-
bicin, vincristine and prednisone (CHOP). Incorporating
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Rituximab into conventional chemotherapy for follicular
lymphoma has lead to higher response rates and longer
durations of remission compared with chemotherapy
alone [6]. The success of Rituximab suggests that addi-
tional targeted therapeutics might improve the efficacy
of cytotoxic regimens.
Constitutively active NF-B in lymphoma is known
to induce resistance to intrinsic and extrinsic apoptosis
pathways [7]. NF-B is a transcription factor com-
prised of homo- and heterodimers, p50/p105 (NF-
B1), p52/p100 (NF-B2), c-Rel, RelB, and p65 (RelA)
[8]. Inhibitors of kappa B (IBa, IBb and IBε) con-
tain ankyrin-like repeats that mediate sequestration of
NF-B in the cytosol [9]. The interaction between
IBa and NF-B is regulated by IB kinase (IKK-1
and IKK-2). Phosphorylation of IBa leads to its
degradation and release of NF-B. NF-B is then able
to translocate to the nucleus where it controls a num-
ber of molecules involved in vital cellular functions,
such as proliferation, apoptosis, and resistance to che-
motherapy [10-16].
Clinically, aberrant NF-B activation has been linked
to poor outcome in lymphomas [17,18]. Therefore,
these and other studies prompted us to investigate
potential therapeutic effects of inhibiting components
of the NF-B activation pathway in our lymphoma
models.
Small molecule inhibitors (SMI) are used to selec-
tively target molecules involved in survival pathways.
ML120B (N-[6-chloro-7-methoxy-9H-b-carbolin-8-yl]-
2-methylnicotinamide) is a potent and selective
inhibitor of IKK-2, acting through blockade of the
ATP-binding site in the kinase. ML120B has been
shown to inhibit tumor necrosis factor-a (TNF-a)-
induced nuclear translocation of p65 subunit of NF-B
and block TNF-a-stimulated cytokine production in
human fibroblast-like synovial cell cultures isolated
from patients with rheumatoid arthritis [19]. ML120B
inhibits both baseline and TNF-a-induced NF-B acti-
vation in multiple myeloma cells. It was also shown to
inhibit the growth of multiple myeloma cells in vitro
and in vivo SCID mouse models [20].
In this report, we show that ML120B inhibits the
phosphorylation of IBa, hinders the growth of lym-
phoma cell lines in a concentration- and time-depen-
dent manner and reduces progression out of G0/G1
phase of the cell cycle. More importantly, ML120B
has a synergistic interaction with vincristine, a com-
mon cytotoxic agent used in the treatment of hema-
tological malignancies. Our studies suggest that IKK-
2 inhibition has a therapeutic role in lymphoma
when used alone or in combination with cytotoxic
agents.
Results
Inhibition of IKK-2 Leads to Growth Inhibition of
Lymphoma Cell Lines
In order to determine whether perturbation of the NF-
B activation pathway might play a survival role in our
lymphoma models, we seeded lymphoma cells in cluster
plates and treated the cells with ML120B at 0 to 80 μM.
ML120B inhibited the growth of our cells in a concen-
tration- and time-dependent manner. After 48 hours of
incubation, the IC50 values were 18.8 and 23.2 μM for
WSU-FSCCL and WSU-DLCL2 cells; respectively (Fig-
ure 1A). Accumulation of cells in sub G0/G1 fraction
was not seen, indicating absence of apoptosis (data not
shown). Instead, there was a concentration-dependent
increase in cells arrested at G0/G1 and a reciprocal
decrease of cells in S-phase (Figure 1B). ML120B (40
μM) induced a statistically significant increase of cells in
G0/G1: 14% and 31% in WSU-FSCCL and WSU-DLCL2
(P = 0.02 and 0.01), respectively.
The WSU-FSCCL and WSU-DLCL2 cells exhibit con-
stitutive NF-B activation as shown by the baseline
expression of the phosphorylated form of IBa
(p-IBa). ML120B inhibited phosphorylated IBa in a
concentration-dependent manner within one hour incu-
bation with these cells. At 20 μM, ML120B inhibited
p-IBa by 100% in WSU-FSCCL and 40% in WSU-
DLCL2 compared to control (Figure 1C).
IKK-2 Inhibition in Combination with Conventional
Chemotherapeutic Agents
Since CHOP is currently the standard regimen for lym-
phoma therapy, we chose to investigate the effects of
IKK-2 inhibition in combination with the cytotoxic
components of CHOP in WSU-FSCCL, i.e. cyclopho-
sphamide monohydrate (C), doxorubicin (H), and vin-
cristine (V). The drug concentrations used were adopted
from experiments in the WSU-DLCL2 cells as previously
determined in our lab [21]. When used together, the
IC50 for WSU-DLCL2 were as follows: C = 5.84 pM; H
= 1.5 pM; and V = 260 pM. However, when these drugs
used individually against WSU-FSCCL in this study, we
obtained less than 50% growth inhibitions at 48 hours:
C = 38% (i.e. IC40); H = 24% (i.e. IC25); and V = 39%
(i.e. IC40). WSU-FSCCL cells were pre-incubated with
ML120B for 1 hour at IC50 (18.8 μM) prior to addition
of cytotoxic agents. The M/C combination did not
induce growth inhibition greater than the individual
agents alone (Figure 2A & Table insert D). Similar
results were obtained with M/H combination (Figure 2B
& Table insert D). However, the M/V combination
induced significant growth inhibition greater than either
agent alone (Figure 2C & Table insert D). To determine
if this interaction is synergistic, WSU-FSCCL cells were
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incubated with both agents at varying concentrations
and the fractional effect of both agents alone and in
combination was calculated (Figure 2F). The M/V com-
bination at 20 μM: 260 pM yielded a CI value of 0.225
which correlates with “strong synergism”. Increasing
concentration of the agents yielded “very strong syner-
gism”. Notably, M/V combination at lower concentra-
tion (10/130) also yielded “synergism” (Table insert E in
Figure 2).
ML120B: Vincristine Combination Induces G2/M Cell Cycle
Arrest and Apoptosis
When used alone against the WSU-FSCCL cells, vincris-
tine at 520 pM induced G2/M arrest at 24 hours which
was released at subsequent time points (Figure 3A). Vin-
cristine at its IC40 (260 pM) did not induce significant
G2/M arrest compared to control. Higher concentra-
tions of vincristine (50 nM to 0.2 μM) were previously
shown to induce G2/M arrest in cancer cells [22,23].
Vincristine, at a concentration of 50 nM in our WSU-
FSCCL cells induced a sustained G2/M arrest over the
72 hour incubation period (Figure 3A). In the combina-
tion studies, the general effects on cell cycle were similar
but the magnitude was different depending on the con-
centration of the 2 compounds. The most dramatic
effect was seen with the higher concentrations (M 40
μM: V 520 pM) which showed a significant increase in
G2/M at 24 hrs at the expense of S and G0/G1 (Figure
3B). With further incubation (48 and 72 hrs), there was
relative increase in G0/G1 suggesting that cells arrested
in G2/M at 24 hrs underwent apoptosis. In support of
this interpretation is the increase of cells in sub-G0
Figure 1 ML120B inhibits cell growth, cell cycle progression and phosphorylation of IBa in Lymphoma cell lines. A. IC50 was calculated
by trypan blue exclusion assay for each cell line after 48 h incubation. Cell number (vertical axis) = Mean and SEM [standard error of mean].
B. DNA content was analyzed by PI staining using flow cytometry after 48 h for each cell line. C. Lymphoma cell lines were cultured for
60 minutes with ML120B at the indicated concentrations and whole cell lysates were subjected to Western blot for detection of p-IBa, IBa
and actin (Arrows indicate total IBa).
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shown in Figure 3C. The combination of 40:520 M(μM):
V(pM) induced a G2/M arrest at 24 hours that was not
statistically different from the 50 nM vincristine. The
combination of the two agents had a statistically signifi-
cant concentration- and time-dependent increase in
apoptotic sub G0/G1fraction of cells. The increase in
the apoptotic fraction induced by the combination was
higher compared to that found in both the control and
50 nM vincristine at 24 hours (Figure 3C). At 48 hours,
the M/V combination at 40 μM: 520 pM induced com-
parable apoptosis to the higher concentration of single
agent vincristine (50 nM). However, at 72 hours, the
high concentration of vincristine alone was more effec-
tive. Of special interest is our observation that neither
ML120B nor vincristine alone (at concentrations up to
40 μM and 520 pM, respectively) induced sub G0/G1
accumulation (Figure 3D). Therefore, our data suggest
that the M/V combination induces an initial G2/M
arrest at 24 hours, followed by apoptosis at 48 and
72 hours, leaving a fraction of unaffected cells arrested
in G0/G1. We used TUNEL assay to confirm that apop-
tosis occurred mostly in G2/M. Figure 4A shows the
increasing FITC positive population in treated cells
compared with control (horizontal axis). Total FITC
positive cells also increased with increasing time of
incubation and concentration of M:V. For example, the
total number of FITC positive cells in the highest con-
centration of M:V combination (bottom line, panel B,
Figure 4) increased from 12.75% at 24 h to 43.46% at 48
h and to 51.33% at 72 h. Moreover, there was progres-
sive shift-to-the-right of FITC positive cell population
with increasing incubation indicating increasing intensity
of DNA breaks (apoptosis). Most of the FITC positive
cells were in G2/M phase followed by sub G0/G1
(which indicates late apoptosis). Some apoptosis did
occur from G0/G1 at 72 h. Induction of apoptosis was
Figure 2 ML120B synergizes with the microtubule inhibitor, vincristine. Cell viability was measured by trypan blue exclusion assay over a
72 h incubation period, Mean and standard deviation (SD). WSU-FSCCL cells were exposed to each agent at the indicated concentrations for
72 h or pretreated with ML120B (20 μM) for 60 minutes followed by (A) cyclophosphamide (5.84 pM), (B) doxorubicin (1.5 pM), or (C) vincristine
(260 pM, or 520 pM). D. Student t-test was used to calculate the values for combinational treatments. E. Synergy was calculated using CalcuSyn
V2; CI < 0.9 indicates synergy. ML120B:vincristine synergized at all concentrations used. F. Combinational index (CI) curve according to Chou-
Talalay method (reference 24) used to determine synergy between ML120B and vincristine. A ratio of <0.9 indicates synergy. Abbreviations used:
M = ML120B, C = cyclophosphamide monohydrate, H = doxorubicin, V = vincristine, CTR = control (vehicle-treated cells).
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Figure 3 ML120B:vincristine combination induces cell cycle arrest and apoptosis. Flow cytometric analysis of cell cycle was done following
PI staining of WSU-FSCCL cells. A. WSU-FSCCL cells were exposed to vincristine (V) for the indicated times and concentrations. B. WSU-FSCCL
cells were pretreated with ML120B (M) for 60 minutes followed by vincristine (V) at the indicated concentrations and times. C. Apoptotic cells
(Sub G0) analyzed by PI staining using flow cytometry in WSU-FSCCL for combinational treatments, Mean and standard error of mean (SEM). D.
Apoptotic cells analyzed as in (C) in WSU-FSCCL cells treated with single agents.
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also confirmed independently using 7-amino-actinomy-
cin D (7-AAD) staining as shown in Figure 5.
Mechanism of Interaction Between IKK-2 Inhibition and
Vincristine
To define some of the molecular mechanisms by which
ML120B synergizes with vincristine in WSU-FSCCL
cells, we first evaluated selected markers of apoptosis.
There was only minimal activation of apoptosis execu-
tioner (caspase-3) by each agent alone (Figure 6). How-
ever, the ML120B: vincristine combination induced
caspase-3 cleavage. The combination also significantly
induced PARP cleavage. Both agents, individually and in
combination, enhanced the expression of cleaved cas-
pase 8. These findings support the flow cytometry data
presented in Figures 3, 4, 5 showing that ML120B: vin-
cristine combination induces significant apoptosis
whereas neither agent alone has significant effect at the
concentrations used in this study. These data also sup-
port the synergistic growth inhibitory effect shown in
Figure 2. To explain such synergy, we evaluated the
effects of different treatments on p65 in WSU-FSCCL
cells by western blots and immunofluorescence. As
shown in Figure 6, exposure of cells to ML120B led to
retention of p65 in the cytosol and reduction in nuclear
p65. This finding is consistent with published data [19]
and with our finding that ML120B inhibits the phos-
phorylation, and subsequent degradation, of I-B (Figure
1). Vincristine, on the other hand, decreased the cytoso-
lic p65 expression indicating p65 translocation to the
nucleus and activation of NF-B pathway. This finding
is consistent with published data demonstrating that
vincristine and other microtubule inhibitors activate NF-
B [24]. In the combination treatment where cells are
Figure 4 ML120B:vincristine combination induces apoptosis in G2/M phase cells. WSU-FSCCL cells were pretreated with ML120B (M) for
60 minutes followed by vincristine (V) at indicated concentrations in Panel B then analyzed for Terminal transferase dUTP Nick End Labeling
(TUNEL) staining using flow cytometry. A. Representative histograms using the higher concentrations of M and V; upper panel: untreated, control
cells; lower panel: treated with ML120B (40 μM) and vincristine (520 pM). B. Full data of FITC positive cells by cell cycle phase (sub G0, G0/G1, S,
G2/M) according to PI staining of DNA. The largest FITC positive population in treated cells was in G2/M followed by sub G0.
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exposed to ML120B for one hour prior to vincristine,
p65 was sequestered in the cytosol comparable to levels
of ML120B-alone treated cells. These findings were con-
firmed by immunofluorescence studies (Figure 7) and
led us to hypothesize that ML120B synergizes with vin-
cristine by preventing vincristine-induced activation of
NF-B pathway. As a transcription factor, NF-B con-
trols many molecules that are associated with resistance
to programmed cell [3,17,18].
Antitumor Activity of ML120B in Lymphoma-bearing SCID
Mice
Finally, we determined the efficacy of ML120B in our
lymphoma-bearing xenograft SCID mouse models.
ML120B did not prevent WSU-FSCCL from infiltrating
into the CNS in this systemic model (data not shown).
It was not possible, therefore to determine its systemic
efficacy since the usual cause of animal death is CNS
lymphoma [25]. Conversely, ML120B delayed the
growth of WSU-DLCL2 SC tumors. In Figure 8A, single
day doses did not induce significant tumor growth
delay. However, a 28-day course showed significant
delay in tumor growth compared to single day doses (P
= 0.03) and to control (P = 0.04). To determine whether
our in vitro combination findings correlated in vivo, we
compared ML120B with CHOP at its MTD. Figure 8B,
shows that CHOP and ML120B significantly reduced
tumor load when given alone compared to control (P =
0.003 and 0.006, respectively). ML120B: CHOP combi-
nation significantly delayed tumor growth compared to
control (P = 0.003), CHOP alone (P = 0.003), and
ML120B alone (0.001). This data indicate that IKK-2
inhibition potentiates conventional cytotoxic chemother-
apy effect in vivo.
Figure 5 7-AAD flow cytometric analysis of apoptosis. Representative scattergrams generated from 7-AAd staining of WSU-FSCCL treated
with vincristine at 520 pm (VCR), ML120B at 40 uM (ML) or the combination (ML + VCR) for 72 h (bottom panel left to right). Top panel left (+
control) are heat-treated dead cells; top left (untreated) are live WSU-FSCCL cells from control culture. Within each scattergram, 7-AAD (vertical
axis) separates cells into dead (A, top), apoptotic (B, middle) or live (C, bottom).
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Discussion
In this study we show that inhibition of IKK-2 by a small
molecule inhibitor, ML120B, enhances the cytotoxic
effect of the microtubule inhibitor, vincristine in lym-
phoma cells. IKK-2 inhibition leads to sequestration of
p65 in the cytosol and prevention of vincristine-induced
nuclear translocation. It was previously shown that NF-
B activation is involved in vincristine resistance [26].
This is believed to be due, at least in part, to the positive
effect of NF-B on cell cycle progression [27].
There are multiple approaches to target IKK-2/NF-
B pathway. Several specific IKK-2 inhibitors are
under development (reviewed by Karin et. al [28]).
These inhibitors have a wide range of IC50 in relation-
ship to inhibiting IKK-2. For example, the IC50 of
SPC-839, PS-1145, and BMS-345541 are 62 nM, 0.15
μM and 0.3 μM, respectively. ML120B inhibits IKK-2
at an IC50 of 62 nM. ML120B, in the nM range is
highly specific to IKK-2, but is capable of inhibiting
IKKε and other enzymes at an IC50 greater that 100
μM [29]. Other novel SMIs, such as GS143 suppress
IBa ubiquitination, but not IBa phosphorylation.
Thus, inhibition of NF-B activation is as complex as
the activation pathway itself with multiple sites as
targets for inhibition [30].
The present study makes several key observations
regarding IKK-2 as a potential therapeutic target in lym-
phoma. First, we demonstrated that inhibition of IKK-2
by ML120B can cause growth inhibition in a concentra-
tion- and time-dependent manner. The cause of the
growth inhibition was due to the increase of cells in G0/
G1 phase of the cell cycle. Our results suggest that
ML120B alone acts by blocking cell growth and not via
apoptosis. Second, we demonstrated that ML120B can
inhibit constitutive activation of NF-B in indolent and
aggressive lymphoma cell lines in a concentration
dependent manner similar to what was observed in
myeloma cells [20]. These observations suggest a broad
application of IKK-2 inhibition in lymphoid tumors.
Interestingly, our data shows that IKK-2 inhibition
synergizes the cytotoxic effects of microtubule inhibitor,
vincristine. This synergy was found at 1/100 the dose of
vincristine alone required to induce comparable G2/M
arrest and apoptosis (520 pM in combination with
ML120B (40 μM) vs 50 nM when used alone, Figure
3A-C). Furthermore, our results suggest that the
ML120B: vincristine combination induces cell cycle
arrest followed by apoptosis out of G2/M. Vincristine is
a microtubule depolymerizing agent. It was shown that
depolymerization of microtubules activates NF-kB and
induces NF-kB-dependent gene expression [31]. Our
data indicate that prevention of vincristine-induced
nuclear translocation of p65 and activation of NF-B is
a major mechanism of synergy between IKK-2 inhibition
and vincristine. This synergy is selective since we did
not observe similar interaction between IKK-2 inhibition
and cyclophosphamide or doxorubicin. Cell death
induced by the ML120B: vincristine combination is
through the apoptosis pathway since there was evidence
for caspase 3 and PARP cleavage (Figure 6). Constitutive
activation of NF-B in lymphoma and consequent acti-
vation of downstream molecules like cIAP2 [32], p21
[33], and Bcl-2 [12] increases the threshold for apopto-
sis. This cell survival mechanism is accentuated by
exposure of cells to vincristine [24,33]. IKK-2 inhibition,
by sequestering NF-B in the cytosol and consequent
down regulation of pro-survival molecules, lowers the
threshold of apoptosis in response to cytotoxic agents
like vincristine (Figures 3, 4, 5).
In vivo, we showed that ML120B: CHOP combination
was well tolerated by the animals and induced higher
anti-tumor efficacy compared with each agent alone in
our WSU-DLCL2-SCID model (Figure 8). We have pre-
viously shown that genistein (30 μM) sensitizes DLCL2
cells to CHOP [24]. Bharti et al., have shown that curcu-
min, a natural inhibitor of NF-B, may sensitize the
Figure 6 IKKb inhibition in combination with Vincristine
reduces p65 nuclear translocation and induces apoptosis. WSU-
FSCCL cells were incubated with ML120B or Vincristine alone, or
pretreated with ML120B (60 minutes) then cultured with Vincristine
at indicated concentrations for 24 h. Total cell lysates were
subjected to Western blot for detection of indicated protein using
actin as a loading control. Nuclear and cytosolic p65 protein
fractions were extracted from total cell lysates. GAPDH is used as a
cytosolic loading control.
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cytotoxic effects of vincristine (50 μM) [34]. Sanda et al.,
showed that IKK inhibition by ACHP (10 μM) led to
growth inhibition of MM cells and potentiation of vin-
cristine cytotoxicity [35].
Conclusion
In summary, our study shows the feasibility of inhibit-
ing a constitutively active NF-B pathway in lym-
phoma cells. Such inhibition is associated with
therapeutically beneficial biological effects in vitro and
in vivo. When used alone, ML120B elicited modest
therapeutic gains. However, there was significant
synergy with the microtubule inhibitor, vincristine.
Our data indicate that approaches to NF-B pathway
inhibition are best used in combination with cytotoxic
chemotherapy rather than single agents. The major
future challenge is to develop a more effective IKK-2
inhibitor with lower cellular IC50 in order to make
them more attractive clinically.
Materials and methods
Cell Culture and Reagents
The cell lines used in the study have been previously
described; Follicular Lymphoma (WSU-FSCCL) [36] and
Diffuse Large Cell Lymphoma (WSU-DLCL2) [37]; The
WSU-FSCCL cell line has been karyotyped at least 4
times since our initial publication in 1993. The recent
analysis in September of 2009 revealed the same chro-
mosomal abnormalities as previously reported; 47,XY,
+der(1)i(1)(q10)del(1)(q32),t(1;13)(p31;q12),del(6)
(q21q27),t(8;11)(q24;q22),t(14;18)(q32;q21). The WSU-
DLCL2 has been similarly karyotyped several times
since its establishment in 1990. The cell line acquired
an additional abnormality, add(8q24), that was detected
for the first time in 1997. Since then the karyotype pro-
file has remained stable with no further changes. The
most recent karyotype in September of 2009 revealed:
48,XY,t(1;2)(p36;q37),der(3)t(3;7)(q13;p15),t(4;14)(q27;
q32),+7,i(7)(p10),der(7)t(3;7)(q21;p11.2),+8,add(8)(q24),
Figure 7 Immunofluorescence microscopy images of WSU-FSCCL cells. Top panel represents control cells after 48 h of culture; top left,
tubulin staining; top center, NF-B p65; top right, overlay of tubulin and p65. Bottom panel represents images of WSU-FSCCL cells after 48 h of
treatment with ML120B (40 μM) and vincristine (520 pM). ML120B was added 60 minutes prior to vincristine: Bottom left are vincristine-alone
treated cells showing disruption of microtubules and translocation of p65 to the nucleus as indicated by yellow-orange color. Bottom center:
ML120B plus vincristine treatment showing sequestration of p65 in the cytoplasm in most cells. Bottom right: is same as bottom center except
with DAPI counterstain to demarcate the nuclei and confirm absence of p65 from nuclei in most cells.
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t(14;18)(q32;q21),del(15)(q26.1),del(16)(q22)[10].
Furthermore, fluorescent in situ hybridization (FISH)
using LSI MYC dual color break-apart DNA probe
(Vysis Inc.) revealed a deletion of the telomeric 3’ region
of CMYC gene most likely due to unbalanced transloca-
tion affecting the CMYC gene region. Cells were main-
tained in RPMI-1640 medium containing 10% heat-
inactivated fetal bovine serum (FBS), 1% L-glutamine,
100 U/ml penicillin G and 100 μg/ml streptomycin and
incubated at 37°C in a humidified incubator with 95%/
5% CO2. Primary antibody specific for Actin was
obtained from Santa Cruz Biotechnology, (Santa Cruz,
CA). Primary antibodies specific for Caspase-3, Caspase-
9, PARP, p-IBa and IBa were obtained from Cell
Signaling, (Danvers, MA). G3PDH was obtained from
Trevigen, Inc (Gaithersburg, MD). Protein concentra-
tions were determined using the Micro BCA protein
assay (Pierce Chemical Company, Rockford, IL).
Cyclophosphamide monohydrate was obtained from
Mead Johnson (Evansville, IN). Doxorubicin hydrochlor-
ide was obtained from Bedford Inc (SA, Australia). Vin-
cristine was obtained from Pharma Inc. (Bloomington,
MN). ML120B was synthesized by Millennium Pharma-
ceuticals, Inc (Cambridge, MA) and dissolved in DMSO.
Concentration of DMSO in the final culture was 0.44%.
Western Blot Analysis
Proteins obtained from cell extracts were collected 24,
48, or 72 h after single or combination treatment with
the IKK-2 inhibitor (ML120B) and vincristine in lysis
buffer containing protease inhibitors. Cytosolic protein
extracts were prepared from control and treated cells
using Nuclear/Cytosolic Fractionation Kit according to
manufacturer’s protocol (BioVision, Mountain View,
CA). All proteins were resolved using 12% SDS-PAGE
and transferred to Hybond C-extra membranes
Figure 8 In vivo activity of ML120B alone, and with CHOP in WSU-DLCL2-SCID xenograft mouse model, tumor weights represent
Mean and standard error of mean (SEM). A. Activity of ML120B as single agent: WSU-DLCL2 tumors were xenografted s.c. into 10 ICR SCID
mice/group on day 0 and dosing was initiated on day 7. ML120B was administered p.o. 120 mg/kg one dose on day 7 (× 1), 60 mg/kg twice
(BID) on day 7 (× 2), and 60 mg/kg BID for 28 days starting on day 7 (× 28). Each point represents mean tumor weight of animal in each group
± SEM. B. ML120B plus CHOP treatment: Xenografts were developed as in A and treatment started on day 7. CHOP was administered at
maximum tolerated doses (MTD) as previously defined (see Material and Methods), ML120B was administered p.o. 60 mg/kg BID for 28 days (as
in A), ML120B in combination with CHOP at MTD.
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(Amersham Life Science, Arlington Heights, IL). Mem-
branes were blocked with 5% milk in Tris buffer saline
containing 0.05% Tween 20 (TBST) for 1 h at 25°C and
incubated overnight at 4°C with rabbit anti-caspase 9
(H-170, Santa Cruz), rabbt anti-caspase 8 (H-134, Santa
Cruz), rabbit anti-PARP (#9542, Cell Signaling), mouse
anti-caspase 3 (#9668, Cell Signaling) or rabbit anti-NF-
B (H-286, Santa Cruz) in 2% Bovine serum albumin in
TBST (1:1000 dilutions in BSA-TBST). Following
incubation, membranes were washed with TBST and
incubated with corresponding horseradish peroxidase-
conjugated secondary antibody (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA; 1:5000 dilution in 5% milk-TBST)
for 1 h at 25°C and then washed before proteins were
visualized using picoglow HRP substrate (Michigan
Diagnostics, LLC, Royal Oak, MI).
Flow Cytometric Analysis of Cell Cycle and Apoptosis
Cell cycle analysis and sub G0/G1 DNA content were
determined by flow cytometry using propidium iodide
(PI) staining. Cells were grown in the presence or
absence of ML120B or vincristine then centrifuged and
washed. The cells were then fixed with 75% ice-cold etha-
nol overnight and stained with 50 μg of PI and analyzed.
To determine DNA fragmentation (as indication of apop-
tosis) induced by treatment agents, we utilized standard
terminal deoxynucleotidyl transferase of dUTP nick end
labeling (TUNEL) assay and propidium iodide (PI) stain-
ing. The kit used in this method (ApoDirect In Situ DNA
Fragmentation Assay Kit, BioVision, Mountain View, CA;
Catalog #K402-50) utilizes terminal deoxynucleotidyl
transferase (TdT) to catalyze incorporation of DUTP at
the 3’-hydroxyl ends of the fragmented DNA. The fluor-
escein-labeled DNA was detected by flow cytometry
(horizontal axis in Figure 4). PI staining was simulta-
neously used to separate cells into G0/G1, S, G2 M and
sub-G0 compartments based on DNA content (vertical
axis, Figure 4). The dual staining (dUTP and PI) allowed
us to assign dUTP-positive cells to a cell cycle phase. In
this method, it is accepted that dUTP-positive cells are
considered apoptotic [38]. To confirm induction of apop-
tosis, we stained WSU-FSCCL cells with 7-AAD as pre-
viously published from our laboratory [39]. All flow
cytometry analysis of cells was done on FACScan (Bec-
ton-Dickinson, San Jose, CA).
Fluorescence Microscopy
WSU-FSCCL cells, treated and untreated, were har-
vested, washed once with PBS and fixed for 10 min with
3.7% formaldehyde in PBS. All procedures were carried
out at room temperature. Following fixation, cells were
washed 3 times with PBS, blocked for 45 min with 0.5%
BSA in PBS and then incubated for 3 hr in 200 μl PBS
containing 0.1% saponin (PBS-S), 1 μg/ml each of two
primary antibodies, mouse anti-human NF-Bp65 and
rabbit anti-tubulin. After incubation with primary anti-
bodies, cells were carefully washed 3 times with PBS-S
and then resuspended in PBS-S containing 5% goat sera
and 10 μg/ml each of two fluorescently-labeled second-
ary antibodies and DAPI (10 μg/ml) for nuclear staining,
if used. Cells were incubated for 1 hour, washed X3
with PBS-S and then fixed for 1 min with 3.7% formal-
dehyde. Following the final fixation, cells were washed 3
times with PBS containing no saponin. Cell suspensions
were mounted on 1% gelatin-coated slide, dried, sealed
with coverslips and visualized using an Olympus BX40
microscope equipped with laser light and fluorescence
filter cubes for UV, green and red fluorescence. Visual
recordings were captured separately using an RT-Spot
Color Camera (Diagnostic Instruments, Inc, Sterling
Heights, MI) and merged using Super Spot software
(Diagnostic Instruments) to complete the overlay and
final pictures.
All primary antibodies were purchased from Cell Sig-
naling Technologies (Danvers, MA). Slow Fade Light,
DAPI and Alexa Fluor 488 (green) and Alexa Fluor 568
(red) fluorescently labeled secondary antibodies were
purchased from Molecular Probes (a division of InVitro-
gen, Carlsbad, CA).
Establishment and Propagation of Xenografts
3-4 week old female ICR mice with severe combined
immune deficiency (SCID) were purchased from Taco-
nic Farms (Germantown, NY). Animals were housed in
special protective environment and left to adapt for few
days before beginning the experiments. To initiate the
WSU-DLCL2-SCID xenografts, (5-10) × 10
6 WSU-
DLCL2 cells in serum-free RPMI 1640 medium were
injected subcutaneously (SC) in the flank areas of each
animal. Palpable tumors were detected by clinical exam-
ination in about 2 weeks. When tumor weight reached
1000-1500 mg, animals were euthanized; tumors dis-
sected out, placed in RPMI 1640 medium in sterile
environment and minced into small fragments (20-
30 mg each). To propagate the xenografts, tumor frag-
ments were implanted SC, using a trocar, into flanks of
3-4 week old female ICR-SCID mice. Forty animals
were implanted with WSU-DLCL2 tumors for the single
agent (ML120B alone) experiment and forty for the
combination study (CHOP plus ML120B). The WSU-
FSCCL-SCID is a systemic model which is established
by injecting 107 WSU-FSCCL cells in serum-free med-
ium intravenously via tail vein of ICR-SCID mice. The
growth pattern and assessment of response of this
model to ML120B were the same as previously
published from our laboratory [25].
Efficacy Trial Design
WSU-DLCL2 tumor-bearing animals were randomly
assigned to control or one of 3 treatment
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dose/schedules of ML120B; 10 animals in each group.
Therapy was started one week after tumor implantation.
Group 1 received one dose of ML120B at 120 mg/kg.
Group 2 received 60 mg/kg twice (every 12 hours).
Group 3 received 60 mg/kg twice a day for 28 days. All
treatments were given through oral gavage. ML120B
compound was dissolved in 5% (hydroxypropyl) methyl-
cellulose. Control group animals received vehicle alone.
CHOP MTD in SCID mice was previously determined
in our laboratory [21] for one injection (i.e.40 mg/kg, i.
v. cyclophosphamide; 3.3 mg/kg,i.v. doxorubicin; 0.5
mg/kg,i.v. vincristine; and 0.2 mg/kg orally prednisone
every day for 5 days). Animals were monitored 3 times
per week for signs of toxicity, weight changes and
tumor measurements. They were euthanized to avoid
discomfort if the tumor burden reached ~2000 mg
(approximately 10% of the body weight). All animal
experiments were done according to protocols approved
by the Animal Investigation Committee (AIC) of Wayne
State University.
Statistical Analysis
Statistical significance of drug-treated versus control
measurements was determined by the student t-test.
The interaction between ML120B and vincristine was
analyzed using Calcusyn V2 software program to deter-
mine if the combinations were synergistic. Calcusyn is
based on the Chou-Talalay method [40], which calcu-
lates a combinational index (CI) to indicate synergistic
effects where CI < 0.9, is considered synergistic. Survival
functions were estimated using the Kaplan-Meier
method and compared by the log-rank test. P-values
<0.05 were considered statistically significant.
All statistical analyses were evaluated using GraphPad
Prism 4 (San Diego, CA).
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